Insider Buying: Lexicon Pharmaceuticals, Inc. (LXRX) Director Buys 180,727 Shares of Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Public Equities L.P. Invus acquired 180,727 shares of the company’s stock in a transaction on Friday, November 17th. The stock was acquired at an average cost of $10.11 per share, with a total value of $1,827,149.97. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Public Equities L.P. Invus also recently made the following trade(s):

  • On Friday, November 10th, Public Equities L.P. Invus acquired 145,680 shares of Lexicon Pharmaceuticals stock. The stock was acquired at an average cost of $9.74 per share, with a total value of $1,418,923.20.
  • On Tuesday, November 14th, Public Equities L.P. Invus acquired 575,946 shares of Lexicon Pharmaceuticals stock. The stock was acquired at an average cost of $9.64 per share, with a total value of $5,552,119.44.

Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) traded down $0.35 during mid-day trading on Friday, hitting $9.65. 763,005 shares of the company were exchanged, compared to its average volume of 811,534. Lexicon Pharmaceuticals, Inc. has a 52-week low of $8.07 and a 52-week high of $18.00. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.66 and a quick ratio of 1.65.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. The firm had revenue of $26.94 million during the quarter, compared to analysts’ expectations of $27.97 million. During the same period in the previous year, the company earned ($0.35) EPS. The firm’s revenue for the quarter was down 2.8% compared to the same quarter last year. research analysts expect that Lexicon Pharmaceuticals, Inc. will post -1.45 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://sportsperspectives.com/2017/11/17/insider-buying-lexicon-pharmaceuticals-inc-lxrx-director-buys-180727-shares-of-stock.html.

A number of equities analysts have commented on the stock. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. Wedbush reissued an “outperform” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, October 5th. Needham & Company LLC reissued a “buy” rating and issued a $21.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Sunday, September 17th. BidaskClub cut shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 10th. Finally, Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. Lexicon Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $28.75.

Several hedge funds have recently added to or reduced their stakes in the stock. FMR LLC boosted its stake in shares of Lexicon Pharmaceuticals by 0.9% during the 2nd quarter. FMR LLC now owns 15,785,280 shares of the biopharmaceutical company’s stock worth $259,668,000 after purchasing an additional 137,421 shares during the period. Vanguard Group Inc. boosted its stake in shares of Lexicon Pharmaceuticals by 16.3% during the 1st quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock worth $59,773,000 after purchasing an additional 585,222 shares during the period. USS Investment Management Ltd purchased a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter worth about $57,705,000. Eagle Asset Management Inc. boosted its position in Lexicon Pharmaceuticals by 0.3% in the 2nd quarter. Eagle Asset Management Inc. now owns 2,861,065 shares of the biopharmaceutical company’s stock valued at $47,064,000 after buying an additional 8,756 shares during the period. Finally, State Street Corp boosted its position in Lexicon Pharmaceuticals by 19.9% in the 2nd quarter. State Street Corp now owns 1,967,255 shares of the biopharmaceutical company’s stock valued at $32,363,000 after buying an additional 326,088 shares during the period.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply